NCT03737994 2026-03-18
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Genentech, Inc.
University College, London
ETOP IBCSG Partners Foundation
AstraZeneca
Hunan Province Tumor Hospital
Hunan Province Tumor Hospital
Gruppo Oncologico Italiano di Ricerca Clinica
Hospital Israelita Albert Einstein
Fondazione per la Medicina Personalizzata
Hoffmann-La Roche